Investors

Polaris Group (TWSE: 6550) (the “Group” or “Polaris”) was incorporated in the British Cayman Islands on February 9, 2006 with a par value of NT$10 per share. The Group and its key subsidiaries include Polaris Pharmaceuticals (Taiwan), Inc., Genovior Biotech Corporation, Polaris Pharmaceuticals, Inc., DesigneRx Pharmaceuticals, Inc., Nanotein Technologies, Inc., DesigneRx Pharmaceuticals (Chengdu), Inc., and North Star Pharmaceuticals, Ltd.. The Group’s principal business activities are the manufacture and sale of new drugs, peptide drugs, API, generics, and CDMO and other biotechnology services and drug testing. The Group’s core research is the novel cancer target drug ADI-PEG 20, which is currently undergoing human clinical trials for various cancers worldwide, various peptide product development and manufacturing optimization, and biopharmaceutical CDMO services.